Roche Stock Falls as Breast Cancer Drug Fails Trial Goals

Roche's shares declined sharply after its breast cancer drug, giredestrant, failed a key trial. The drug didn't show meaningful progress when combined with Ibrance. Despite this, analysts see long-term potential in its use as an add-on treatment, with revenue possibly reaching $6.5 billion annually.

In a significant setback, Roche's shares suffered a steep drop exceeding 7% at one point on Monday following the announcement that its breast cancer drug, giredestrant, did not pass a critical trial. The trial aimed to demonstrate that the drug, when paired with Pfizer's Ibrance, could effectively slow disease progression compared to standard therapies, but it fell short.

Despite the negative outcome, analysts like Barclays' James Gordon view the dip as a buying opportunity, pointing to the underrecognized potential of giredestrant as an adjuvant therapy. Previous studies showed promise when the drug was used as a second-line treatment, cutting the risk of tumor recurrence.

However, Roche faces stiff competition with players like AstraZeneca entering the market with alternatives such as camizestrant. This trial's results cast doubts on the optimistic projections surrounding giredestrant. Nonetheless, Roche remains committed, seeking approval from the U.S. Food and Drug Administration based on earlier successful trials.

(With inputs from agencies.)